Co-founder & CSO Parag Mallick Granted 280,000 Options, Maintains 17.6% Stake

summarizeSummary

Nautilus Biotechnology's Co-founder and Chief Science Officer, Parag Mallick, was granted 280,000 stock options, reinforcing his significant 17.6% beneficial ownership in the company.

check_boxKey Events

• Insider Option Grant

  Co-founder and Chief Science Officer Parag Mallick was granted options to purchase 280,000 shares of common stock on March 2, 2026.

• Significant Ownership Stake

  Dr. Mallick's beneficial ownership now stands at 22,557,411 shares, representing 17.6% of the company's outstanding common stock.

• Updated Disclosure

  This filing amends previous Schedule 13D disclosures, providing an updated view of a key executive's stake and recent compensation.

auto_awesomeAnalysis

This Schedule 13D/A filing updates the beneficial ownership of Parag Mallick, Co-founder and Chief Science Officer, to 17.6% of Nautilus Biotechnology's outstanding shares. The key new event is the grant of 280,000 stock options to Dr. Mallick on March 2, 2026. This grant, valued at approximately $764,400 based on the current stock price, serves as a significant compensation component and further aligns his interests with long-term shareholder value. His substantial ownership stake, combined with this new option grant, signals strong insider commitment to the company's future.